Toll Free: 1-888-928-9744
Published: Mar, 2015 | Pages:
35 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Neurim Pharmaceuticals Ltd - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Neurim Pharmaceuticals Ltd - Product Pipeline Review - 2015', provides an overview of the Neurim Pharmaceuticals Ltd's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Neurim Pharmaceuticals Ltd's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Neurim Pharmaceuticals Ltd including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Neurim Pharmaceuticals Ltd's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Neurim Pharmaceuticals Ltd's pipeline products Reasons to buy - Evaluate Neurim Pharmaceuticals Ltd's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Neurim Pharmaceuticals Ltd in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Neurim Pharmaceuticals Ltd's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Neurim Pharmaceuticals Ltd and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Neurim Pharmaceuticals Ltd - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Explore the dormant and discontinued projects of Neurim Pharmaceuticals Ltd and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of table 4 List of Figures 4 Neurim Pharmaceuticals Ltd Snapshot 5 Neurim Pharmaceuticals Ltd Overview 5 Key Information 5 Key Facts 5 Neurim Pharmaceuticals Ltd - Research and Development Overview 6 Key Therapeutic Areas 6 Neurim Pharmaceuticals Ltd - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Neurim Pharmaceuticals Ltd - Pipeline Products Glance 11 Neurim Pharmaceuticals Ltd - Late Stage Pipeline Products 11 Phase III Products/Combination Treatment Modalities 11 Neurim Pharmaceuticals Ltd - Clinical Stage Pipeline Products 12 Phase II Products/Combination Treatment Modalities 12 Phase I Products/Combination Treatment Modalities 13 Neurim Pharmaceuticals Ltd - Early Stage Pipeline Products 14 Preclinical Products/Combination Treatment Modalities 14 Neurim Pharmaceuticals Ltd - Drug Profiles 15 melatonin ER 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 piromelatine 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 Neu-120 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Neu-107 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Neu-164 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Neu-240 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Neu-AZ1 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 NeuP-12 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Neurim Pharmaceuticals Ltd - Pipeline Analysis 25 Neurim Pharmaceuticals Ltd - Pipeline Products by Target 25 Neurim Pharmaceuticals Ltd - Pipeline Products by Route of Administration 27 Neurim Pharmaceuticals Ltd - Pipeline Products by Molecule Type 28 Neurim Pharmaceuticals Ltd - Pipeline Products by Mechanism of Action 29 Neurim Pharmaceuticals Ltd - Recent Pipeline Updates 30 Neurim Pharmaceuticals Ltd - Dormant Projects 32 Neurim Pharmaceuticals Ltd - Locations And Subsidiaries 33 Head Office 33 Other Locations & Subsidiaries 33 Appendix 34 Methodology 34 Coverage 34 Secondary Research 34 Primary Research 34 Expert Panel Validation 34 Contact Us 34 Disclaimer 35
List of Tables Neurim Pharmaceuticals Ltd, Key Information 5 Neurim Pharmaceuticals Ltd, Key Facts 5 Neurim Pharmaceuticals Ltd - Pipeline by Indication, 2015 8 Neurim Pharmaceuticals Ltd - Pipeline by Stage of Development, 2015 9 Neurim Pharmaceuticals Ltd - Monotherapy Products in Pipeline, 2015 10 Neurim Pharmaceuticals Ltd - Phase III, 2015 11 Neurim Pharmaceuticals Ltd - Phase II, 2015 12 Neurim Pharmaceuticals Ltd - Phase I, 2015 13 Neurim Pharmaceuticals Ltd - Preclinical, 2015 14 Neurim Pharmaceuticals Ltd - Pipeline by Target, 2015 26 Neurim Pharmaceuticals Ltd - Pipeline by Route of Administration, 2015 27 Neurim Pharmaceuticals Ltd - Pipeline by Molecule Type, 2015 28 Neurim Pharmaceuticals Ltd - Pipeline Products by Mechanism of Action, 2015 29 Neurim Pharmaceuticals Ltd - Recent Pipeline Updates, 2015 30 Neurim Pharmaceuticals Ltd - Dormant Developmental Projects,2015 32 Neurim Pharmaceuticals Ltd, Subsidiaries 33
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.